Since 2011, several of these tracers received regulatory approval to assist in the diagnosis of dementia (in particular, for ruling out AD in favor of other forms of dementia when the amyloid-β signal was absent in the presence of cognitive impairment, in line with the revised Research Diagnostic Criteria for AD) [1].
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}